Alteon's ED trial still on hold

ALT said FDA maintained its clinical hold on the Phase IIa EMERALD trial of alagebrium to treat erectile dysfunction (ED) following a review of additional preclinical toxicity data that were submitted in August. ALT said in its 10-Q for the quarter ended June 30 that if it does not resume enrollment in EMERALD, it will evaluate moving into different indications and/or returning to its preclinical library to choose new compounds to develop. The company also disclosed that it is seeking strategic alternatives. At June 30, ALT had $11.6 million in cash and a six-month net loss of $8 million. ...